Epigenetics and colorectal cancer pathogenesis

Kankana Bardhan, Kebin Liu

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Colorectal cancer (CRC) develops through a multistage process that results from the progressive accumulation of genetic mutations, and frequently as a result of mutations in the Wnt signaling pathway. However, it has become evident over the past two decades that epigenetic alterations of the chromatin, particularly the chromatin components in the promoter regions of tumor suppressors and oncogenes, play key roles in CRC pathogenesis. Epigenetic regulation is organized at multiple levels, involving primarily DNA methylation and selective histone modifications in cancer cells. Assessment of the CRC epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has thousands of abnormally methylated genes. Although relatively less is known about the patterns of specific histone modifications in CRC, selective histone modifications and resultant chromatin conformation have been shown to act, in concert with DNA methylation, to regulate gene expression to mediate CRC pathogenesis. Moreover, it is now clear that not only DNA methylation but also histone modifications are reversible processes. The increased understanding of epigenetic regulation of gene expression in the context of CRC pathogenesis has led to development of epigenetic biomarkers for CRC diagnosis and epigenetic drugs for CRC therapy.

Original languageEnglish (US)
Pages (from-to)676-713
Number of pages38
JournalCancers
Volume5
Issue number2
DOIs
StatePublished - Jun 1 2013

Fingerprint

Epigenomics
Colorectal Neoplasms
Histone Code
DNA Methylation
Chromatin
Wnt Signaling Pathway
Gene Expression Regulation
Oncogenes
Genetic Promoter Regions
Genes
Neoplasms
Biomarkers
Gene Expression
Mutation
Pharmaceutical Preparations

Keywords

  • Colorectal cancer
  • DNMT
  • Epigenetic therapy
  • HDAC
  • HMTase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Epigenetics and colorectal cancer pathogenesis. / Bardhan, Kankana; Liu, Kebin.

In: Cancers, Vol. 5, No. 2, 01.06.2013, p. 676-713.

Research output: Contribution to journalArticle

Bardhan, Kankana ; Liu, Kebin. / Epigenetics and colorectal cancer pathogenesis. In: Cancers. 2013 ; Vol. 5, No. 2. pp. 676-713.
@article{a97fbc9670664824babe62e52e5f077b,
title = "Epigenetics and colorectal cancer pathogenesis",
abstract = "Colorectal cancer (CRC) develops through a multistage process that results from the progressive accumulation of genetic mutations, and frequently as a result of mutations in the Wnt signaling pathway. However, it has become evident over the past two decades that epigenetic alterations of the chromatin, particularly the chromatin components in the promoter regions of tumor suppressors and oncogenes, play key roles in CRC pathogenesis. Epigenetic regulation is organized at multiple levels, involving primarily DNA methylation and selective histone modifications in cancer cells. Assessment of the CRC epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has thousands of abnormally methylated genes. Although relatively less is known about the patterns of specific histone modifications in CRC, selective histone modifications and resultant chromatin conformation have been shown to act, in concert with DNA methylation, to regulate gene expression to mediate CRC pathogenesis. Moreover, it is now clear that not only DNA methylation but also histone modifications are reversible processes. The increased understanding of epigenetic regulation of gene expression in the context of CRC pathogenesis has led to development of epigenetic biomarkers for CRC diagnosis and epigenetic drugs for CRC therapy.",
keywords = "Colorectal cancer, DNMT, Epigenetic therapy, HDAC, HMTase",
author = "Kankana Bardhan and Kebin Liu",
year = "2013",
month = "6",
day = "1",
doi = "10.3390/cancers5020676",
language = "English (US)",
volume = "5",
pages = "676--713",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Epigenetics and colorectal cancer pathogenesis

AU - Bardhan, Kankana

AU - Liu, Kebin

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Colorectal cancer (CRC) develops through a multistage process that results from the progressive accumulation of genetic mutations, and frequently as a result of mutations in the Wnt signaling pathway. However, it has become evident over the past two decades that epigenetic alterations of the chromatin, particularly the chromatin components in the promoter regions of tumor suppressors and oncogenes, play key roles in CRC pathogenesis. Epigenetic regulation is organized at multiple levels, involving primarily DNA methylation and selective histone modifications in cancer cells. Assessment of the CRC epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has thousands of abnormally methylated genes. Although relatively less is known about the patterns of specific histone modifications in CRC, selective histone modifications and resultant chromatin conformation have been shown to act, in concert with DNA methylation, to regulate gene expression to mediate CRC pathogenesis. Moreover, it is now clear that not only DNA methylation but also histone modifications are reversible processes. The increased understanding of epigenetic regulation of gene expression in the context of CRC pathogenesis has led to development of epigenetic biomarkers for CRC diagnosis and epigenetic drugs for CRC therapy.

AB - Colorectal cancer (CRC) develops through a multistage process that results from the progressive accumulation of genetic mutations, and frequently as a result of mutations in the Wnt signaling pathway. However, it has become evident over the past two decades that epigenetic alterations of the chromatin, particularly the chromatin components in the promoter regions of tumor suppressors and oncogenes, play key roles in CRC pathogenesis. Epigenetic regulation is organized at multiple levels, involving primarily DNA methylation and selective histone modifications in cancer cells. Assessment of the CRC epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has thousands of abnormally methylated genes. Although relatively less is known about the patterns of specific histone modifications in CRC, selective histone modifications and resultant chromatin conformation have been shown to act, in concert with DNA methylation, to regulate gene expression to mediate CRC pathogenesis. Moreover, it is now clear that not only DNA methylation but also histone modifications are reversible processes. The increased understanding of epigenetic regulation of gene expression in the context of CRC pathogenesis has led to development of epigenetic biomarkers for CRC diagnosis and epigenetic drugs for CRC therapy.

KW - Colorectal cancer

KW - DNMT

KW - Epigenetic therapy

KW - HDAC

KW - HMTase

UR - http://www.scopus.com/inward/record.url?scp=84878822005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878822005&partnerID=8YFLogxK

U2 - 10.3390/cancers5020676

DO - 10.3390/cancers5020676

M3 - Article

VL - 5

SP - 676

EP - 713

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

ER -